Haohai biological technology acquires full ownership of ophthalmic subsidiary

Shanghai Haohai Biological Technology Company Limited announced the acquisition of the remaining 20% equity interest in its subsidiary, bringing its total ownership to 100%. The acquisition, valued at RMB74,000,000, was completed on November 7, 2025. This transaction is considered a connected transaction under Chapter 14A of the Listing Rules. Following the acquisition, the subsidiary will become a wholly-owned entity of the company, enhancing management and operational efficiency within the ophthalmic products sector.

The acquisition price of RMB74,000,000 was negotiated based on an updated valuation, reflecting changes in the ophthalmic market since 2023, particularly a decrease in gross profit margins and performance following the inclusion of intraocular lens products in national centralized procurement. The company’s financial results show a net profit of RMB22,006,200 for the year ended December 31, 2024.

The company’s share capital remained stable at 38,529,240 H shares as of November 7, 2025. The acquisition aligns with the company's strategy to strengthen its position in the high-value ophthalmic consumables market.